解離性大動脈瘤、dissecting aortic aneurysm

WordNet

the 4th letter of the Roman alphabet (同)d

PrepTutorEJDIC

deuteriumの化学記号

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/03/16 23:29:59」(JST)

wiki ja

[Wiki ja表示]

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. C型肝炎ウイルス感染治療のための直接作用型抗ウイルス薬 direct acting antivirals for the treatment of hepatitis c virus infection
2. C型肝炎ウイルス感染に対する試験的治療 investigational therapies for hepatitis c virus infection
3. 遺伝子2型および3型慢性C型肝炎の治療レジメン treatment regimens for chronic hepatitis c virus genotypes 2 and 3
4. 消化器学および肝臓学の最新情報 whats new in gastroenterology and hepatology
5. 遺伝子4型、5型、および6型慢性C型肝炎ウイルスの治療レジメン treatment regimens for chronic hepatitis c virus genotypes 4 5 and 6

English Journal

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.

Buti M1, Agarwal K2, Horsmans Y3, Sievert W4, Janczewska E5, Zeuzem S6, Nyberg L7, Brown RS Jr8, Hézode C9, Rizzetto M10, Paraná R11, De Meyer S12, De Masi R13, Luo D13, Bertelsen K13, Witek J13.Author information 1Liver Unit, Department of Internal Medicine, Hospital Valle Hebron and Ciberehd del Institut Carlos III, Barcelona, Spain. Electronic address: mbuti@vhebron.net.2Institute of Liver Studies, Kings College Hospital, London, England.3Clinical Pharmacology Unit, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.4Gastroenterology and Hepatology Unit, Monash Medical Centre and Monash University, Melbourne, Australia.5Outpatients Clinic for Hepatology, Outpatients Clinic for Hepatology, ID Clinic, Myslowice, Poland.6Department of Medicine I, Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany.7Hepatology Research Department, Kaiser Permanente, San Diego, California.8Department of Hepatology and Gastroenterology, Columbia University College of Physicians and Surgeons, New York, New York.9Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Créteil, France.10Department of Hepatology and Gastroenterology, University of Torino, Torino, Italy.11Gastro-Hepatology Unit, Medical School, Federal University of Bahia, Bahia, Brazil.12Janssen Infectious Diseases BVBA, Beerse, Belgium.13Janssen Research & Development LLC, Titusville, New Jersey.AbstractBACKGROUND & AIMS: We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis.
Gastroenterology.Gastroenterology.2014 Mar;146(3):744-753.e3. doi: 10.1053/j.gastro.2013.11.047. Epub 2013 Dec 4.
BACKGROUND & AIMS: We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis.METHODS: Patients were randomly assigned to groups
PMID 24316262

Differential Sensitivity of 5'UTR-NS5A Recombinants of Hepatitis C Virus Genotypes 1-6 to Protease and NS5A Inhibitors.

Li YP1, Ramirez S1, Humes D1, Jensen SB1, Gottwein JM1, Bukh J2.Author information 1Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of International Health, Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.2Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital and Department of International Health, Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: jbukh@sund.ku.dk.AbstractBACKGROUND & AIMS: Hepatitis C virus (HCV) therapy will benefit from the preclinical evaluation of direct-acting antiviral (DAA) agents in infectious culture systems that test the effects on different virus genotypes. We developed HCV recombinants comprising the 5' untranslated region-NS5A (5-5A) from genotypes 1-6 and 2a(JFH1) NS5B-3' untranslated region, and tested the effects of NS3 protease and NS5A inhibitors on these recombinants.
Gastroenterology.Gastroenterology.2014 Mar;146(3):812-821.e4. doi: 10.1053/j.gastro.2013.11.009. Epub 2013 Nov 18.
BACKGROUND & AIMS: Hepatitis C virus (HCV) therapy will benefit from the preclinical evaluation of direct-acting antiviral (DAA) agents in infectious culture systems that test the effects on different virus genotypes. We developed HCV recombinants comprising the 5' untranslated region-NS5A (5-5A
PMID 24262279

Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection.

Gane EJ1, Stedman CA2, Hyland RH3, Ding X3, Svarovskaia E3, Subramanian GM3, Symonds WT3, McHutchison JG3, Pang PS3.Author information 1New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand. Electronic address: edgane@adhb.govt.nz.2Gastroenterology Department, Christchurch Hospital and University of Otago, Christchurch, New Zealand.3Gilead Sciences, Inc, Foster City, California.AbstractBACKGROUND & AIMS: We evaluated an all-oral regimen comprising the nucleotide polymerase inhibitor sofosbuvir (SOF) with the NS5A inhibitor ledipasvir (LDV) or the NS5B non-nucleoside inhibitor GS-9669 in patients with genotype 1 hepatitis C virus (HCV) infection.
Gastroenterology.Gastroenterology.2014 Mar;146(3):736-743.e1. doi: 10.1053/j.gastro.2013.11.007. Epub 2013 Nov 18.
BACKGROUND & AIMS: We evaluated an all-oral regimen comprising the nucleotide polymerase inhibitor sofosbuvir (SOF) with the NS5A inhibitor ledipasvir (LDV) or the NS5B non-nucleoside inhibitor GS-9669 in patients with genotype 1 hepatitis C virus (HCV) infection.METHODS: A total of 113 patients
PMID 24262278

Japanese Journal

分散アレーアンテナシステムの固定局適用に関する検討(符号化技術特集セッション,移動衛星通信,放送,誤り訂正,無線通信一般)

鈴木義規,須崎皓平,廣瀬貴史,小林聖
電子情報通信学会技術研究報告. SAT, 衛星通信 111(179), 111-116, 2011-08-18
本報告では,移動局向けに提案している複数のアンテナ装置を連係動作させる分散アレーアンテナシステムに関して,固定局への適用に特化したアンテナシステム構成を提案する。提案システムは既存のアンテナ装置および変復調装置の利用を可能とするため,連係動作をつかさどる分散アレー制御装置をIF帯で構成し,アンテナ装置で発生するアンテナ装置間の相対位相変動を自局の衛星折り返し信号の受信レベルをモニタすることで補償す …
NAID 110008801152

SCFβTrCP mediates stress-activated MAPK-induced Cdc25B degradation

Uchida Sanae,Watanabe Nobumoto,Kudo Yasusei,Yoshioka Katsuji,Matsunaga Tsukasa,Ishizaka Yukihito,Nakagama Hitoshi,Poon Randy Y.C.,Yamashita Katsumi
Journal of Cell Science 124(16), 2816-2825, 2011-08-15
… Point mutation of these Ser residues to alanine (Ala) abolished the JNK-induced ubiquitylation by SCFβTrCP, and point mutation of DAG to AAG or DAA eradicated both βTrCP binding and ubiquitylation. …
NAID 120003386981

Related Pictures

DAA Deutsche Angestellten-Akademie GmbH DAA Stuttgart DAA-SH Karte Berufsfachschule für Rettungsassistenten DAA MEGABOL DAA STIN ACIDO D-ASPARTICO Congratulations to the DAA for winning DAA structure

★リンクテーブル★

リンク元	「解離性大動脈瘤」「dissecting aortic aneurysm」
関連記事	「D」「DA」

「解離性大動脈瘤」

　　[★]

英: dissecting aortic aneurysm DAA, dissecting aneurysm of the aorta DA
同: 剥離性大動脈瘤、大動脈解離
関: 急性大動脈解離, 解離性動脈瘤

分類

DeBakey
Stanford

病因

1. 動脈硬化性
2. 嚢胞性中膜壊死：特に若年者で、かつ Marfan(マルファン)症候群を合併していることが多い。

症状

PHD.354 HIM.1565

突発性、激烈な前胸部痛(Stanford A型)・背部痛(Stanford B型)。移動性。
血管の閉塞症状(頚動脈：意識障害、麻痺、上腸間膜動脈：悪心・嘔吐、上腹部痛、下血、腎動脈：乏尿、血尿、腸骨動脈：下肢痛、チアノーゼなど)
循環器症状：血圧↑　←　狭窄部より近位の血圧が増大する(IMD.474)
消化器症状：悪心・嘔吐(痛みから交感神経刺激)
腎臓：乏尿(腎血流減少、交感神経興奮)、血尿
全身症状：疼痛と共にショックを起こす、発汗(交感神経刺激)
ARをきたした場合：(急性ARによる)呼吸困難、血痰、動悸
DeBakey I型・DeBakeyI II型(Stanford A型)：大動脈弁閉鎖不全、脳卒中発作、鎖骨下動脈閉塞による上肢の疼痛(身体所見として左右上肢の血圧差)
DeBakey III型(Stanford B型)：III型では肝・腎不全、消化器症状、(大動脈分岐部)背部痛、下肢の阻血(下肢の疼痛)